Core Insights - Femasys Inc. will showcase its innovative fertility solutions at the ASRM 2025 Scientific Congress & Expo in San Antonio, Texas from October 25-29 [1][4] - The company is highlighting its next-generation artificial insemination solution, FemaSeed, which has demonstrated more than double the pregnancy rates of traditional intrauterine insemination (IUI) in cases of low male sperm count [2][5] - Femasys has expanded its FemaSeed portfolio to include various kits that enable gynecologists to perform sperm preparation and offer FemaSeed directly in their practices [3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally [5] - The company has a patent-protected portfolio of therapeutic and diagnostic products, including FemaSeed and FemVue, aimed at improving reproductive health [5] - Femasys has received regulatory approvals for its products in multiple regions, including the U.S., Europe, UK, Canada, Israel, Australia, and New Zealand [2][6] Product Highlights - FemaSeed is positioned as a safe, accessible, and cost-effective alternative to IUI, particularly for patients with low male sperm count [2] - The FemBloc product, a non-surgical permanent birth control solution, received full regulatory approval in Europe, the UK, and New Zealand in 2025 [6] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success for FemBloc [6]

Core Insights - Femasys Inc. has announced a partnership with Medical Electronic Systems LLC to launch the FemSperm Analysis Kit, enhancing its infertility product line and enabling gynecologists to perform in-office sperm handling for FemaSeed Intratubal Insemination [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [3] - The company’s fertility portfolio includes FemaSeed Intratubal Insemination, which has demonstrated over double the pregnancy rates compared to traditional intrauterine insemination (IUI) in cases of low male sperm count [3] Product Details - The FemSperm Analysis Kit completes the FemSperm product family, which includes the Setup Kit and Insemination Prep Kit, allowing gynecologists to conduct sperm preparation and analysis in their practices [1][2] - FemaSeed is positioned as a first step in the fertility journey, providing a safe, accessible, and cost-effective alternative to IUI, and is authorized for use in multiple regions including the U.S., Europe, UK, Canada, Israel, Australia, and New Zealand [2] Recent Developments - Femasys has received full regulatory approval for its FemBloc permanent birth control in Europe, the UK, and New Zealand, marking it as the first non-surgical, in-office alternative to traditional surgical sterilization [4] - The FemChec diagnostic product complements FemBloc by providing an ultrasound-based test to confirm procedural success, with initial clinical trials showing compelling effectiveness and high satisfaction [4]